CDC/ACIP [to 29 Sep 2018]

CDC/ACIP [to 29 Sep 2018]

MMWR News Synopsis for September 27, 2018
Influenza Vaccination Coverage Among Health Care Personnel — United States, 2017–18 Influenza Season
CDC, the Advisory Committee on Immunization Practices (ACIP), and the Healthcare Infection Control Practices Advisory Committee recommend that all healthcare workers get an annual flu vaccine. If you work in health care and get the flu, you can spread it to others even if you don’t feel sick. By getting vaccinated, you help protect yourself, your family at home, and your patients. CDC, ACIP, and the Healthcare Infection Control Practices Advisory Committee recommend all health care workers receive an annual flu vaccine. Vaccinating healthcare workers can a) reduce influenza-related morbidity and mortality among health care workers, b) reduce work absences, and c) help protect patients. Flu vaccination coverage during the 2017-2018 flu season was 78.4 percent among healthcare workers, which is a 15 percentage-point increase from the 2010-2011 flu season. However, estimates have stayed relatively similar during the past four seasons. Coverage was consistently higher among healthcare workers in hospital settings and lowest among healthcare workers in long-term-care settings.

Influenza and Tdap Vaccination Coverage Among Pregnant Women — United States, April 2018 
Many pregnant women are unvaccinated. They and their babies continue to be vulnerable to influenza and pertussis infections with potentially serious complications including hospitalization and death. Doctors are encouraged to strongly recommend vaccines that their pregnant patients need, and either administer needed vaccines or refer patients to a vaccination provider. CDC and the Advisory Committee on Immunization Practices (ACIP) recommend two vaccines for pregnant women: 1) a flu vaccine for women who are or might be pregnant during the flu season and 2) a Tdap (tetanus, diphtheria, and acellular pertussis) vaccine during every pregnancy, between 27 and 36 weeks gestation (preferably earlier in this period). To assess influenza and Tdap vaccination coverage among pregnant women during the 2017–18 influenza season, CDC analyzed data from an Internet panel survey. Only about half (49.1 percent) of women reported receiving influenza vaccine before or during their pregnancy. Additionally, a little over half (54.4 percent) reported receiving Tdap during their pregnancy. Women who reported receiving a provider offer of vaccination had higher vaccination coverage than women who received a recommendation but no offer and women who did not receive a recommendation.

Meningococcal Disease Surveillance in Men Who Have Sex with Men — United States, 2015–2016
Men who have sex with men (MSM), including those with HIV, have increased meningococcal disease rates compared to non-MSM. Identifying MSM among meningococcal disease patients and improving collection of data on HIV status for all cases will help researchers understand the epidemiology and risk factors for meningococcal disease among MSM. Studies have shown that MSM are at increased risk for meningococcal disease in the United States. However, until now, researchers have not well described the epidemiology of disease in this group because gender of sex partners and/or sexual orientation have not historically been collected through routine meningococcal disease surveillance. From 2015-2016, 271 meningococcal disease cases were reported in men ages ≥18 years; among them, sufficient information to identify MSM status was available for 124 (45.8 percent). Overall, 48 (17.7 percent) cases occurred in MSM. MSM, including those with HIV, have increased meningococcal disease rates compared to non-MSM. During investigations of meningococcal disease, CDC encourages state and local health departments to assess HIV status of all patients and identify MSM among male patients ages ≥16 years.

Barriers to Receipt of Prenatal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) Among Mothers of Infants Aged <4 Months with Pertussis — California, 2016
Getting immunized against whooping cough at the earliest opportunity during 27-36 weeks gestation of each pregnancy is the best way to protect young infants against this disease. Prenatal care providers should make a strong recommendation for Tdap to all pregnant women. If Tdap is not stocked onsite, providers should make every effort to refer patients to an accessible site covered by the mother’s insurance and then follow up to ensure she is immunized. Infants are at highest risk for hospitalization and death due to whooping cough (pertussis). To protect newborns, CDC recommends that all pregnant women be immunized against whooping cough as early as possible during 27-36 weeks gestation of each pregnancy. This California study showed that only 30 percent of mothers whose infants developed pertussis were appropriately vaccinated. Women whose prenatal clinics stocked Tdap vaccine were more likely to be vaccinated. Women with Medicaid insurance were less likely to be vaccinated than were those with private insurance, even when treated in clinics that stocked Tdap vaccine.

China CDC 

China CDC
New website launched…no “news” or “announcements” page identified.
National Health Commission of the People’s Republic of China
Selected Updates/Press Releases
Police to help hospitals reduce patient disputes
Public security departments will improve cooperation with health authorities to reduce medical disputes between patients and hospitals, Li Jingsheng, chief of security administration at the Ministry of Public Security, said at a conference on Sept 26 with several departments.

Chinese first lady calls for global efforts against TB
Peng Liyuan, wife of Chinese President Xi Jinping, addressed the United Nations General Assembly high-level meeting on ending tuberculosis (TB) via a video on Sept 26, calling for global efforts to put an end to the epidemic.

Abortions in China decreased in past five years
The number of abortions in China has decreased in the past five years, but the high proportion of young adults and teenagers undergoing the procedure remains a vexing issue.

Chinese doctors to provide free eye surgeries in 6 countries
China has announced plans to send medical teams to provide free surgery to 3,000 cataract patients in six countries involved in the Belt and Road Initiative in the next three years.

China to become world’s largest country of organ transplants in 2020
China is expected to have the most organ transplant surgeries in 2020, said Huang Jiefu, director of the China National Organ Donation and Transplantation Committee.


AERAS  [to 29 Sep 2018]
25 September 2018
GSK candidate vaccine helps prevent active pulmonary tuberculosis in HIV negative adults in phase II study
Today, GSK and Aeras reported that GSK’s M72/AS01E candidate vaccine significantly reduced the incidence of pulmonary tuberculosis disease in HIV-negative adults with latent tuberculosis infection in ongoing phase IIb clinical trial testing.
[See Milestones above for detail]
BMGF – Gates Foundation  [to 29 Sep 2018]
No new digest content identified.
Bill & Melinda Gates Medical Research Institute    [to 29 Sep 2018]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
CARB-X   [to 29 Sep 2018]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
09.24.2018  |
CARB-X calls for new ‘open science’ era in antibacterial innovation: Sharing scientific data will help speed the delivery of new antibiotics and other life-saving products to fight superbugs
Achaogen will share valuable LpxC compounds and data with Forge Therapeutics, with both companies leading the ‘open science’ initiative among CARB-X-funded companies
CEPI – Coalition for Epidemic Preparedness Innovations  [to 29 Sep 2018]
Posted on 27TH SEP 2018 by Mario Christodoulou
CEPI Awards Contract Worth Up To USD$19 million to Oxford University and Janssen Vaccines to Develop MERS, Lassa, and Nipah Vaccines
OSLO (Norway), Oxford (UK)
CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a collaboration with The Jenner Institute at the University of Oxford and Janssen Vaccines & Prevention B.V.—part of the Janssen Pharmaceutical Companies of Johnson & Johnson—through which they will receive funding to advance the development and manufacture of a vaccine against Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Preclinical development of novel vaccines against Lassa and Nipah viruses will also be undertaken as part of this collaboration.
Oxford has already initiated clinical development of the MERS-CoV vaccine, with funding from the UK Department of Health and Social Care, and a phase 1 clinical trial of the vaccine is underway in the UK. Under the terms of the Framework Partnering Agreement for the collaboration, Oxford and Janssen will receive $14.6 million from CEPI to support manufacturing of a phase 2 batch and preparation for stockpiling of a MERS-CoV vaccine candidate. Dependent on phase 1 results, CEPI will have the option to provide additional investment for a phase 2 trial and manufacture of an investigational vaccine stockpile that would be available for use in the event of an outbreak. Janssen’s proprietary vaccine-manufacturing platform will enable rapid and efficient production of large volumes of vaccines. Should CEPI exercise its option to provide support for further clinical development, Oxford will undertake phase 2 testing of the vaccine, in partnership with the King Abdullah International Medical Research Centre (KAIMRC) in Riyadh, Kingdom of Saudi Arabia, and the Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme at Kilifi, Kenya.
As part of the collaboration, CEPI will also provide funding of up to $2.1 million to support the preclinical development of a Lassa vaccine and up to $2.0 million to support the preclinical development of a Nipah vaccine…
EDCTP    [to 29 Sep 2018]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
28 September 2018
EDCTP Prizes 2018 awarded at Ninth Forum
EDCTP awarded its 2018 prizes for research excellence and the Pascoal Mocumbi Prize at the opening ceremony of the Ninth Forum on Monday 17 September. Dr Leonardo Simão and Prof. Marcel Tanner, the EDCTP High Representatives for Africa and Europe, presented…
27 September 2018
EDCTP-funded R&D partnerships to tackle infectious disease in Sub-Saharan Africa, 2003-2018
On 17 September 2018 at the High-Level Meeting to discuss a third EDCTP programme in Lisbon, Portugal, Dr Michael Makanga, EDCTP’s Executive Director, presented a collection of success stories illustrating EDCTP’s contribution to the fight against poverty-related infectious diseases over…
Emory Vaccine Center    [to 29 Sep 2018]
No new digest content identified.
European Medicines Agency  [to 29 Sep 2018]
News and press releases

Harnessing the potential of real world data through a ‘learning healthcare system’
Real world data (RWD) hold the promise to substantially increase the effectiveness and efficiency of all processes in the development and utilisation of medicines, from research and development, to regulatory decision-making, pricing and reimbursement decisions to use in medical practice. However, to realise the full potential of RWD requires a ‘learning healthcare system’, write the European Medicines Agency’s (EMA) Executive Director and Senior Medical Officer, as well as heads of three national EU agencies, and academia, payer, and Organisation for Economic Co-operation and Development (OECD) representatives, in a paper published in Clinical Pharmacology and Therapeutics.

A ‘learning healthcare system’, based on electronic health records and other routinely collected healthcare data, would allow RWD to be continuously fed into the system, ensuring that with every new patient treated, we know more overall about the practice of medicine.

Such judicious use of RWD would complement the traditional evidence from randomised clinical trials, for  the benefit of all stakeholders involved in the development and use of medicines, from patients and healthcare professionals to regulators, health-technology assessment bodies, payers, academic researchers and research-based pharmaceutical industry. The authors highlight the need to tear down the current barrier between the structured research setting and everyday medical practice, and instead use data gathered in everyday practice to generate new knowledge and answer research questions.

To achieve this, the healthcare systems must be ready in terms of technology to collect data, of a methodology to analyse information and governance in particular regarding aspects such as protection of personal data, consent, ethics and data access.
The authors therefore call for all stakeholders to join in a coordinated effort, at international level, to accelerate the implementation of such a model of a ‘learning healthcare system’.

Clinical Pharmacology and Therapeutics: Data rich, information poor; can we use electronic health records to create a learning healthcare system for pharmaceuticals?

EMA to launch new corporate website on 27 September 2018
European Vaccine Initiative  [to 29 Sep 2018]
25 September 2018
EVI Annual Report 2017 now available
We are pleased to share with you the EVI Annual Report 2017.
FDA [to 29 Sep 2018]
September 28, 2018
FDA in Brief: FDA modernizes clinical trial designs and approaches for drug development, proposing new guidance on the use of adaptive designs and master protocols
[See Milestones above for detail]

September 27, 2018 –
Statement by FDA Commissioner Scott Gottlieb, M.D., on preparations for the upcoming flu season and vaccinations
September 24, 2018 –
FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases
The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to enhance the development of medical products for patients with rare diseases. These new grants were awarded to principal investigators from academia and industry across the country…
   The FDA awarded the grants through the Orphan Products Clinical Trials Grants Program. This program is funded by Congressional appropriations and encourages clinical development of drugs, biologics, medical devices or medical foods for use in rare diseases. The grants are intended for clinical studies evaluating the safety and effectiveness of products that could either result in, or substantially contribute to, the FDA approval of products targeted to the treatment of rare diseases. Grant applications were reviewed and evaluated for scientific and technical merit by more than 100 rare disease experts, which included representatives from academia, the National Institutes of Health and the FDA…
Fondation Merieux  [to 29 Sep 2018]
No new digest content identified.
Gavi [to 29 Sep 2018]
28 September 2018
UBA Foundation and Gavi launch a new partnership for Africa
The UBA Foundation and Gavi will leverage the United Bank for Africa’s network and expertise to invest in Africa’s health system, starting with Nigeria.
Why hepatitis B vaccination should be Plan A in the fight against liver cancer
27 September 2018
Gavi at the UNGA: driving political leadership
27 September 2018
GHIT Fund   [to 29 Sep 2018]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
September 27, 2018
GHIT Fund Invests in FIND and Fujifilm for Development of Innovative Rapid Diagnostic Tool for Tuberculosis.
TOKYO, JAPAN (September 27, 2018)—The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximately 420 million yen (US$3.8 million) for a highly sensitive rapid diagnostic kit for tuberculosis (TB) known as TB-LAM, being developed by Japan’s Fujifilm Corporation and Switzerland’s Foundation for Innovative New Diagnostics (FIND)…

Global Fund [to 29 Sep 2018];&country=
Global Fund Supports Brave Commitments to Ending TB
26 September 2018
The Global Fund is joining leaders who converge in New York today to commit to speeding up global collaboration in the fight against TB, a preventable disease that killed 1.6 million people in 2017.
Hilleman Laboratories   [to 29 Sep 2018]
Hilleman Labs announces publication of original research on Heat Stable Rotavirus Vaccines
Hilleman Laboratories today announced the publication of original research as well as expert commentary on development of Heat Stable Rotavirus Vaccine (HSRV).
Human Vaccines Project   [to 29 Sep 2018]
Towards a Universal Influenza Vaccine: Lessons from the Great Influenza Pandemic of 1918 to Now
November 15-16, 2018 I Nashville, TN
The Human Vaccines Project is hosting a scientific summit featuring prominent researchers and thought leaders to discuss cutting-edge influenza research. The 2-day meeting will bring together leading scientists, clinicians and public health specialists including: John Barry, James E. Crowe, Jr., Senator Bill Frist, and Laurie Garrett.  Find a full agenda at:
IAVI  [to 29 Sep 2018]
No new digest content identified.

No new digest content identified.

IVAC  [to 29 Sep 2018]
No new digest content identified.
IVI   [to 29 Sep 2018]
No new digest content identified.
JEE Alliance  [to 29 Sep 2018]
No new digest content identified.
MSF/Médecins Sans Frontières  [to 29 Sep 2018]
Selected Press Releases/Statements
One of the world’s biggest paediatric intensive care units is full
Press Release 25 Sep 2018
:: Magaria hospital is the only health facility available in a region of 700,000 to one million people, around 20 per cent of whom are aged under five
:: Of the 730 children currently admitted, 208 are critically ill and mortality rates remain alarmingly high
:: It’s likely that hundreds more children are seriously ill in the community and not getting the care they need

Global leaders must make bold commitments at first-ever UN tuberculosis summit
Press Release 25 Sep 2018
:: World leaders are meeting in New York this week for the first-ever high-level summit on tuberculosis
:: TB is the world’s deadliest infectious disease, killing 1.6 million in 2017, but is drastically under-funded
:: MSF implores leaders at the summit to urgently scale up TB diagnosis and treatment, and commit more resources

NIH  [to 29 Sep 2018]
September 26, 2018
Combination HIV antibody infusions safely maintain viral suppression in select individuals
— HIV did not develop resistance to experimental treatment.

NIH releases strategic plan to address tuberculosis research
September 26, 2018 — TB is the leading infectious cause of death worldwide.
[See Milestones above for detail]

NIH-funded genome centers to accelerate precision medicine discoveries
September 25, 2018 — Part of the All of Us Research Program, centers will sequence 1 million genomes.
The All of Us Research Program awarded funds totaling $28.6 million to establish three genome centers around the country. These centers will begin to generate genomic data from biosamples contributed by the program’s participants. Ultimately, this information will become a critical component in the program’s precision medicine research platform, a national resource to support studies on a variety of important health questions. The All of Us Research Program is part of the National Institutes of Health…
The new All of Us Research Program Genome Centers will be led by:
:: Baylor College of Medicine, Houston, with Johns Hopkins University, Baltimore, and The University of Texas Health Science Center at Houston (UTHealth)
:: The Broad Institute, Cambridge, Massachusetts, with Color, Burlingame, California, and the Laboratory for Molecular Medicine at Partners HealthCare, Cambridge, Massachusetts
:: Northwest Genomics Center at the University of Washington, Seattle..

PATH  [to 29 Sep 2018]
Sept. 27, 2018
Global rotavirus vaccine options expand with World Health Organization prequalification of new vaccine from India
Thermostable rotavirus vaccine ROTASIIL® now available for procurement by UN and Gavi
SEATTLE, PATH welcomes the World Health Organization’s (WHO’s) prequalification of the thermostable rotavirus vaccine, ROTASIIL®, manufactured by Serum Institute of India. The vaccine, which prevents severe rotavirus-induced diarrhea in infants, provides an innovative and affordable option to the global market as it is the first rotavirus vaccine that does not require constant refrigeration and will help meet the critical public health goal of improving vaccine supply worldwide…

September 25, 2018 by PATH
Vietnam welcomes two locally produced vaccines for seasonal and pandemic influenza
International collaboration announces successful clinical trial results with licensure expected in 2019
Nha Trang, Vietnam, September 25, 2018—The Institute of Vaccines and Medical Biologicals (IVAC), World Health Organization (WHO), international global health organization PATH, and the Biomedical Advanced Research and Development Authority (BARDA) within the US Department of Health and Human Services, today joined leaders from the Ministry of Health (MOH), the National Institute of Hygiene and Epidemiology (NIHE), and the Pasteur Institute in Ho Chi Minh City (PIHCM) to announce results from two different Phase 2/3 clinical trials of locally produced seasonal and pandemic influenza vaccine candidates. Overall results showed both vaccine candidates to be acceptably safe and capable of prompting an immune response in healthy adults…

Sabin Vaccine Institute  [to 29 Sep 2018]
No new digest content identified.
UNAIDS [to 29 Sep 2018]
28 September 2018
Building faith-based partnerships to end AIDS and TB among children and adolescents
PEPFAR: the first 15 years
27 September 2018
Learning lessons from the AIDS response to control NCDs
26 September 2018
An opportunity to end two of the world’s deadliest infectious diseases: TB and HIV
Uniting for every woman and every child
25 September 2018
First ladies of Africa working to stop new HIV infections among children

UNICEF  [to 29 Sep 2018]
Selected Press Releases/Reports/Statements
Press release
UNICEF teams up with Ebola survivors to help stop spread of deadly outbreak in the Democratic Republic of the Congo
[See Milestones above for detail]

Press release
Remarks by Henrietta H. Fore, UNICEF Executive Director at the High-Level Meeting on Tuberculosis
As prepared for delivery
[See Milestones above for detail]

Press release
New roadmap to prevent and treat tuberculosis in children and adolescents
In 2017, almost one million children fell ill and over 200,000 children under 15 died of tuberculosis
[See Milestones above for detail]

Vaccine Confidence Project  [to 29 Sep 2018]
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia  [to 29 Sep 2018]
September 2018
Vaccine Update for Providers
This newsletter is meant to keep you up to date on issues related to vaccines quickly and easily.
Wellcome Trust  [to 29 Sep 2018]
Published: 27 September 2018
Collaboration was key to success in latest Public Engagement Fund awards
In August, we made the second set of awards under our new Public Engagement Fund scheme. Greer Roberts and Alexandra Parsons pull out some patterns we saw in the applications and have tips for future applicants.

Opinion / Published: 27 September 2018
This is TB’s moment and it must be seized
Two scientific breakthroughs and a global meeting on tuberculosis mean there is an opportunity to move TB from the doldrums, says Wellcome’s Director Jeremy Farrar. But great science needs to be matched by greater global commitment, ambition and political will.
… But now, thanks to the prodigious efforts of two international research teams, two critical milestones have been reached:
:: results of promising clinical trials of a new candidate vaccine (opens in a new tab)
:: a major study sequencing 10,000 TB genomes (opens in a new tab) from patients across 16 countries – work key to the rapid drug sensitivity testing needed to stop the rise and spread of drug-resistant strains of TB…
The Wistar Institute   [to 29 Sep 2018]
Press Release
Virion Therapeutics, LLC Raises $5 Million to Develop Checkpoint Inhibitor Powered Vaccine Therapies for Treatment of Virally Induced Infectious Diseases & Cancers
PHILADELPHIA — (Sept. 26, 2018) — A new Philadelphia-based start-up, Virion Therapeutics, LLC spun out of The Wistar Institute, will work to advance innovative, immune-based therapies for the treatment of chronic viral-associated cancers and viral infections utilizing the first genetically encoded checkpoint inhibitor that can be given via vaccination. Virion is co-founded by Hildegund C.J. Ertl, M.D., professor in the Vaccine & Immunotherapy Center at Wistar, along with life science entrepreneurs Andrew D. Luber, Pharm.D., and Bernard Rudnick, MBA…

World Organisation for Animal Health (OIE)   [to 29 Sep 2018]
The United Against Rabies collaboration builds skills and knowledge in rabies-endemic countries towards achievement of zero human rabies deaths
On the occasion of the 12th World Rabies Day, the United Against Rabies collaboration highlights the critical role that intersectoral collaboration must play if the world is to be rid of human rabies deaths by 2030.
Paris/Geneva/Rome/Manhattan, 28 September 2018 – The United Against Rabies collaboration, consisting of the World Health Organization (WHO), World Organisation for Animal Health (OIE), Food and Agriculture Organization of the United Nations (FAO), and Global Alliance for Rabies Control (GARC), has been taking action following the launch in June of Zero by 30: the global strategic plan to end human deaths from dog-mediated rabies by 2030. The plan provides a phased, all-inclusive, intersectoral approach to eliminate human deaths from dog-mediated rabies by 2030. It leverages the work of the four aforementioned organizations to facilitate coordination across the institutions. Its aim is to offer an integrated response to country needs through empowering, engaging and enabling them to lead and strengthen elimination efforts.  The approach limits duplication and improves efficiencies…

BIO    [to 29 Sep 2018]
No new digest content identified.
DCVMN – Developing Country Vaccine Manufacturers Network  [to 29 Sep 2018]
27 September 2018
DCVMN engaged in open dialogue with ICDRA about challenges and opportunities for alignment of procedures for vaccine registration
Dublin, September 4th 2018 – The organizers of the International Conference of Drug Regulatory Authorities (ICDRA) [1] 2018 invited the DCVMN regulatory expert working group to join the pre-ICDRA session on “Enabling access to innovative medical products in resource-limited settings” and present the recently published study, conducted in collaboration with IFPMA [2], on the challenges for the registration of vaccines in emerging countries [3]. A DCVMN representative, Ms. Iin Susanti, delivered the lecture and participated in a panel discussion, elaborating on opportunities and future options for regulatory convergence in addressing the challenges, while respecting regulatory requirements…

IFPMA   [to 29 Sep 2018]
27 September 2018
The R&D-based biopharmaceutical industry welcomes the UN Declaration on NCDs and calls for innovative financing
As an official UN interlocutor that shares knowledge and expertise to improve global health, IFPMA welcomes the strong re-affirmation of the commitment of governments to take steps to reduce premature mortality from chronic diseases by 2030 and strongly supports the declaration’s emphasis on orienting health systems towards the achievement of universal health coverage (UHC)…

R&D-based biopharmaceutical industry welcomes UN Declaration on TB Partnerships are key to foster innovation and
26 September 2018
The R&D-based biopharmaceutical industry welcomes the political declaration and reaffirms its commitment to the global fight against TB. To deliver on our common goal, industry stands ready to partner on the three pillars of the WHO End TB Strategy including integrated, patient-centred care and prevention; bold policies and supportive systems; and, in particular, intensified research and innovation…

WIPO and IFPMA Launch New Online Patent-Search Resource to Help Health Agencies Procure Medicines
GENEVA, September 25, 2018 – WIPO and the research-based pharmaceutical industry today launched a new online tool designed to help procurement agencies better understand the global patent status of medicines.
The Patent Information Initiative for Medicines (Pat-INFORMED) is a unique resource where patent holders provide information about patents covering approved medicines through a free, open access database.
This new public database became operational today, along with a platform where procurement agencies can make direct enquiries to companies.
Pat-INFORMED is a partnership between WIPO and the International Federation of Pharmaceutical Manufacturers and Associations, IFPMA, the global trade association representing the research-based pharmaceutical industry. Pat-INFORMED originated in the industry’s efforts to add clarity to patent information about medicines. WIPO’s globally recognized expertise in the organization and public dissemination of patent data will make an important contribution to the accessibility of patent information.
WIPO is hosting the database and providing the resources to ensure its continued development, while IFPMA is working closely with the 20 leading research-based biopharmaceutical companies that have backed this initiative to help ensure a consistent and coordinated approach…
PhRMA    [to 29 Sep 2018]
No new digest content identified.

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Vaccines and Global Health: The Week in Review has expanded its coverage of new reports, books, research and analysis published independent of the journal channel covered in Journal Watch below. Our interests span immunization and vaccines, as well as global public health, health governance, and associated themes. If you would like to suggest content to be included in this service, please contact David Curry at:


No new digest content identified.

Journal Watch

Journal Watch

   Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at:


Enacting high reliability principles while caring for people with Ebola Virus Disease

American Journal of Infection Control
October 2018 Volume 46, Issue 10, p1083-1200, e45-e50

Major Articles
Enacting high reliability principles while caring for people with Ebola Virus Disease
Bonnie Mowinski Jennings, Katherine A. Yeager, Nancye R. Feistritzer, Mary M. Gullatte, Kristy K. Martyn
p1167–1173  Published online: May 18, 2018
:: Infection prevention and control (IPC) are safety issues for patients and staff.
:: A culture of safety was established by enacting high reliability (HR) principles.
:: HR principles helped protect staff caring for patients with Ebola Virus Disease.
:: HR principles might also enhance IPC under ordinary care conditions.